Compounds > phenobarbital

phenobarbital and selegiline

phenobarbital has been researched along with selegiline in 16 studies

Research

Studies (16)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (12.50)	18.7374
1990's	2 (12.50)	18.2507
2000's	8 (50.00)	29.6817
2010's	4 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Lombardo, F; Obach, RS; Waters, NJ	1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Pai, KS; Ravindranath, V	1
Kuroiwa, Y; Yamada, Y; Yamamoto, T; Yoshida, T	1
Kuroiwa, Y; Oguro, T; Yoshida, T	1
Gelowitz, DL; Paterson, IA	1
Frosini, M; Fusi, F; Pessina, F; Sgaragli, GP; Tipton, KF; Valoti, M	1
Haberle, D; Magyar, K; Szökõ, E	1
Bass, AE; Bruce, G; Bylov, IE; Fry, JR; Hammond, AH; Jassi, KL; Kovalenko, SM; Laughton, C; Shaw, PN	1

Reviews

1 review(s) available for phenobarbital and selegiline

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

15 other study(ies) available for phenobarbital and selegiline

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Protection and potentiation of MPTP-induced toxicity by cytochrome P-450 inhibitors and inducer: in vitro studies with brain slices. Brain research, 1991, Aug-02, Volume: 555, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Induction; In Vitro Techniques; L-Lactate Dehydrogenase; Male; Mice; Mixed Function Oxygenases; Monoamine Oxidase Inhibitors; MPTP Poisoning; NADPH-Ferrihemoprotein Reductase; Pargyline; Phenobarbital; Piperazines; Piperonyl Butoxide; Proadifen; Selegiline	1991
Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica; the fate of foreign compounds in biological systems, 1986, Volume: 16, Issue:2 Topics: Amphetamine; Animals; Chromatography, Gas; Cytochrome P-450 Enzyme System; Gas Chromatography-Mass Spectrometry; Hydroxylation; In Vitro Techniques; Male; Methamphetamine; Methimazole; Methylcholanthrene; Microsomes, Liver; Monoamine Oxidase Inhibitors; Phenethylamines; Phenobarbital; Proadifen; Rats; Rats, Inbred Strains; Selegiline	1986
Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: sex and strain differences. Xenobiotica; the fate of foreign compounds in biological systems, 1987, Volume: 17, Issue:8 Topics: Amphetamines; Animals; Chromatography, Gas; Female; In Vitro Techniques; Liver; Male; Methylcholanthrene; Phenethylamines; Phenobarbital; Proadifen; Rats; Rats, Inbred Strains; Selegiline; Sex Factors; Species Specificity	1987
Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration. Pharmacology, biochemistry, and behavior, 1999, Volume: 62, Issue:2 Topics: Animals; Apoptosis; Drug Interactions; Excitatory Amino Acid Agonists; Hypnotics and Sedatives; Kainic Acid; Male; Motor Activity; Neurons; Neuroprotective Agents; Phenobarbital; Rats; Rats, Wistar; Selegiline	1999
Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl. European journal of pharmacology, 2000, Mar-17, Volume: 391, Issue:3 Topics: Animals; beta-Naphthoflavone; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Disulfiram; Enzyme Induction; Enzyme Inhibitors; Ethanol; Fomepizole; In Vitro Techniques; Isoenzymes; Ketoconazole; Mice; Mice, Inbred C57BL; Microsomes, Liver; Monoamine Oxidase Inhibitors; NADH, NADPH Oxidoreductases; NADPH-Ferrihemoprotein Reductase; Phenobarbital; Pyrazoles; Selegiline	2000
The influence of metabolism on the MAO-B inhibitory potency of selegiline. Current medicinal chemistry, 2002, Volume: 9, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Enzyme Induction; Liver; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phenobarbital; Proadifen; Rats; Rats, Wistar; Selegiline	2002
Selectivity of 7-alkoxycoumarins as probe substrates for rat hepatic cytochrome P450 forms is influenced by the substitution pattern on the coumarin nucleus. Xenobiotica; the fate of foreign compounds in biological systems, 2004, Volume: 34, Issue:8 Topics: 7-Alkoxycoumarin O-Dealkylase; Adolescent; Adult; Aged; Animals; beta-Naphthoflavone; Coumarins; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B1; Cytochrome P-450 Enzyme System; Enzyme Induction; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Isoenzymes; Male; Microsomes, Liver; Middle Aged; Molecular Probes; Molecular Structure; Phenobarbital; Rats; Rats, Wistar; Selegiline; Substrate Specificity	2004